Toric IOL enhances refractive outcomes

Article

Rayner, the world's first IOL manufacturer, unveiled a dynamic new brand identity at ESCRS and held a seminar today to highlight the success doctors are having with its range of toric IOLs. Headlined A Roadmap to Success the seminar featured presentations from seven European doctors relating their experiences of using Rayner's toric IOLs.

Rayner, the world's first IOL manufacturer, unveiled a dynamic new brand identity at ESCRS and held a seminar today to highlight the success doctors are having with its range of toric IOLs. Headlined A Roadmap to Success the seminar featured presentations from seven European doctors relating their experiences of using Rayner's toric IOLs.

According to Rod Santos, marketing manager, Rayner has a broad offering in toric, with three lenses; T-flex, M-flex and Sulcoflex. Subjects covered in the seminar included options for the correction of astigmatism and the benefit of multifocal toric IOLs.

For Santos, the highlight of the programme was a presentation by Michael Amon dealing with enhancing refractive outcomes with Rayner's Sulcoflex toric IOL. Amon is the innovator behind the Sulcoflex lense and the seminar marks an important point in the three-year life of the Sulcoflex range.

“Michael Amon had a good idea and brought it to Rayner. Development began three years ago, we took it to market two years ago and, in our ESCRS seminar, we heard very positive report on results and outcomes,” said Santos.

Sulcoflex is a pseudophakic supplementary IOL, manufactured from Rayner's proprietary hydrophilic acrylic co-polymer Rayacryl. It piggy-backs where the patient has already received a primary IOL and has been designed to minimise the potential for contact between the two implants. This reduces the likelihood of induced refractive error and optical aberrations due to optic surface distortion.

OTEurope will be reporting on the doctors' findings in a later edition.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.